Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Rosuvastatin and Dabigatran with BI 1358894
NCT04099732Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bi 1358894 in major depressive disorder (MDD) and borderline personality disorder (BPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve From 0 Extrapolated to Infinity at 72 hours and Maximum Measured Concentration at 72 hours. Started Oct 2019; status: completed.
02
Drugs
bi 1358894
03
Conditions
major depressive disorder (MDD)borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT04099732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04099732.